What do systematic reviews say?

SPRM vs leuprolide acetate

SPRM probably leads to higher adverse effects: SPRM‐associated endometrial changes compared with leuprolide acetate (moderate certainty).

• Selective progesterone receptor modulators (SPRMs) for uterine fibroids 2017 · Cochrane Headline outcomes only
  OR 10.45 [5.38, 20.33]
  1 study · 301 participants
  Moderate

SPRM vs placebo

SPRM may leads to higher adverse effects: SPRM‐associated endometrial changes compared with placebo (low certainty).

• Selective progesterone receptor modulators (SPRMs) for uterine fibroids 2017 · Cochrane Headline outcomes only
  OR 15.12 [6.45, 35.47]
  5 studies · 405 participants
  Low

SPRM vs placebo

• Selective progesterone receptor modulators (SPRMs) for uterine fibroids 2017 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 171 participants
  Moderate

SPRM vs leuprolide acetate

SPRM showed no clear difference in abnormal uterine bleeding: amenorrhoea compared with leuprolide acetate (moderate certainty).

• Selective progesterone receptor modulators (SPRMs) for uterine fibroids 2017 · Cochrane Headline outcomes only
  OR 1.14 [0.6, 2.16]
  1 study · 280 participants
  Moderate

SPRM vs leuprolide acetate

• Selective progesterone receptor modulators (SPRMs) for uterine fibroids 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 281 participants
  Moderate

SPRM vs placebo

• Selective progesterone receptor modulators (SPRMs) for uterine fibroids 2017 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 200 participants
  Moderate

SPRM vs placebo

• Selective progesterone receptor modulators (SPRMs) for uterine fibroids 2017 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 310 participants
  Moderate

SPRM vs placebo

SPRM probably leads to higher abnormal uterine bleeding: amenorrhoea compared with placebo (moderate certainty).

• Selective progesterone receptor modulators (SPRMs) for uterine fibroids 2017 · Cochrane Headline outcomes only
  OR 82.5 [37.1, 183.9]
  7 studies · 590 participants
  Moderate

SPRM vs placebo

• Selective progesterone receptor modulators (SPRMs) for uterine fibroids 2017 · Cochrane Headline outcomes only
  no estimate extracted
  7 studies · 629 participants
  GRADE not reported

SPRM vs leuprolide acetate

• Selective progesterone receptor modulators (SPRMs) for uterine fibroids 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 281 participants
  Moderate

SPRM vs leuprolide acetate

• Selective progesterone receptor modulators (SPRMs) for uterine fibroids 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 281 participants
  Moderate

SPRM vs leuprolide acetate

• Selective progesterone receptor modulators (SPRMs) for uterine fibroids 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 281 participants
  Low

SPRM vs placebo

The review found no eligible studies for this question.

• Preoperative medical therapy before surgery for uterine fibroids 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

SPRM vs placebo

The review found no eligible studies for this question.

• Preoperative medical therapy before surgery for uterine fibroids 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

SPRM vs placebo

• Preoperative medical therapy before surgery for uterine fibroids 2017 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 173 participants
  High

SPRM vs placebo

SPRM may leads to higher preoperative bleeding: (PBAC < 75) ulipristal acetate 5 mg compared with placebo (low certainty).

• Preoperative medical therapy before surgery for uterine fibroids 2017 · Cochrane Headline outcomes only
  OR 41.41 [15.26, 112.38]
  1 study · 143 participants
  Low

SPRM vs placebo

SPRM may leads to higher preoperative bleeding: Reduction in menstrual bleeding (PBAC < 75)… compared with placebo (low certainty).

• Preoperative medical therapy before surgery for uterine fibroids 2017 · Cochrane Headline outcomes only
  OR 78.83 [24.02, 258.74]
  1 study · 146 participants
  Low

SPRM vs placebo

• Preoperative medical therapy before surgery for uterine fibroids 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 22 participants
  Low

SPRM vs placebo

SPRM showed no clear difference in adverse events compared with placebo (low certainty).

• Preoperative medical therapy before surgery for uterine fibroids 2017 · Cochrane Headline outcomes only
  OR 0.05 [0, 1]
  1 study · 241 participants
  Low